| Autor: |
Wickens KL; 1University of Otago,Wellington 6021,New Zealand., Barthow CA; 1University of Otago,Wellington 6021,New Zealand., Murphy R; 2University of Auckland,Auckland 1142,New Zealand., Abels PR; 1University of Otago,Wellington 6021,New Zealand., Maude RM; 4Victoria University,Wellington 6021,New Zealand., Stone PR; 2University of Auckland,Auckland 1142,New Zealand., Mitchell EA; 2University of Auckland,Auckland 1142,New Zealand., Stanley TV; 1University of Otago,Wellington 6021,New Zealand., Purdie GL; 1University of Otago,Wellington 6021,New Zealand., Kang JM; 1University of Otago,Wellington 6021,New Zealand., Hood FE; 1University of Otago,Wellington 6021,New Zealand., Rowden JL; 2University of Auckland,Auckland 1142,New Zealand., Barnes PK; 1University of Otago,Wellington 6021,New Zealand., Fitzharris PF; 5Auckland Hospital,Auckland 1142,New Zealand., Crane J; 1University of Otago,Wellington 6021,New Zealand. |
| Abstrakt: |
The study aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 (HN001) can reduce the prevalence of gestational diabetes mellitus (GDM). A double-blind, randomised, placebo-controlled parallel trial was conducted in New Zealand (NZ) (Wellington and Auckland). Pregnant women with a personal or partner history of atopic disease were randomised at 14-16 weeks' gestation to receive HN001 (6×109 colony-forming units) (n 212) or placebo (n 211) daily. GDM at 24-30 weeks was assessed using the definition of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (fasting plasma glucose ≥5·1 mmol/l, or 1 h post 75 g glucose level at ≥10 mmol/l or at 2 h ≥8·5 mmol/l) and NZ definition (fasting plasma glucose ≥5·5 mmol/l or 2 h post 75 g glucose at ≥9 mmol/l). All analyses were intention-to-treat. A total of 184 (87 %) women took HN001 and 189 (90 %) women took placebo. There was a trend towards lower relative rates (RR) of GDM (IADPSG definition) in the HN001 group, 0·59 (95 % CI 0·32, 1·08) (P=0·08). HN001 was associated with lower rates of GDM in women aged ≥35 years (RR 0·31; 95 % CI 0·12, 0·81, P=0·009) and women with a history of GDM (RR 0·00; 95 % CI 0·00, 0·66, P=0·004). These rates did not differ significantly from those of women without these characteristics. Using the NZ definition, GDM prevalence was significantly lower in the HN001 group, 2·1 % (95 % CI 0·6, 5·2), v. 6·5 % (95 % CI 3·5, 10·9) in the placebo group (P=0·03). HN001 supplementation from 14 to 16 weeks' gestation may reduce GDM prevalence, particularly among older women and those with previous GDM. |
